Form 4: SOPHIA GENETICS CEO Sells Shares for Tax Obligations

SOPHiA GENETICS CEO Jurgi Camblong sold 4,486 ordinary shares to cover tax liabilities from restricted stock unit vesting, as per a 10b5-1 plan.

Summary

• CEO Jurgi Camblong of SOPHiA GENETICS SA sold 4,486 ordinary shares.
• The transaction occurred on March 19, 2026, at a weighted average price of $4.7727 per share.
• The sale was executed to satisfy tax obligations arising from the vesting of restricted stock units on March 18, 2026.
• This transaction was pre-planned under a Rule 10b5-1 trading plan, indicating it was not a discretionary trade.
• Following the sale, Mr. Camblong beneficially owns 3,302,839 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which typically has a neutral impact on sentiment as it does not reflect a change in the executive's investment conviction.

Positives

• The sale was executed under a pre-established Rule 10b5-1 trading plan, indicating a non-discretionary transaction and transparency regarding the executive's trading intentions.

Negatives

• A key executive sold 4,486 shares, which represents a reduction in direct insider holdings, although for a stated tax purpose.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales for tax purposes, especially those arising from the vesting of restricted stock units and executed under a Rule 10b5-1 plan, are common and generally do not signal a change in management's long-term outlook for the company or broader industry trends.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned, tax-related nature mitigates concerns about discretionary selling, thus having a minimal impact on shareholder confidence.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by the CEO to cover tax obligations related to RSU vesting, executed under a Rule 10b5-1 plan. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing.

Keywords

SOPHiA GENETICS, SOPH, Jurgi Camblong, insider trading, Form 4, stock sale, CEO, 10b5-1 plan, tax obligations, restricted stock units